BindingDB logo
myBDB logout

52 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27676469 64 Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.EBI Rheinische Friedrich-Wilhelms-Universit£t Bonn
27376492 15 New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.EBI Universit£ Lyon 1
27100033 40 The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).EBI University of Bonn
26943020 65 Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).EBI University of Bonn
26774038 67 Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.EBI University of Regensburg
25985195 94 Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.EBI The Hong Kong Polytechnic University
22822035 10 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.EBI Chinese Academy of Sciences
23132334 28 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.EBI GlaxoSmithKline
25855895 23 HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).EBI University of Bonn
25311564 30 Thieno[2,3-b]pyridines--a new class of multidrug resistance (MDR) modulators.EBI Institute of Organic Synthesis
25310383 50 Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.EBI Novartis Institutes for Biomedical Research
25272055 18 Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.EBI BMSSI UMR 5086 CNRS/Universit£ Lyon 1
24611893 22 Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.EBI BMSSI UMR5086 CNRS/Universit£ Lyon 1
24184213 71 Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).EBI University of Bonn
23851114 73 Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.EBI University of Bonn
23726026 12 Activity-lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments.EBI Universit£ degli Studi di Bari A. Moro
23374872 27 Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.EBI Universit£ degli Studi di Bari 'A. Moro'
23347803 29 Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters.EBI Universit£ degli Studi di Bari ALDO MORO
15059881 1 Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.EBI St. Jude Children's Research Hospital
15313923 1 Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.EBI The Netherlands Cancer Institute
11437380 2 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.EBI Hungarian Academy of Sciences
15155841 6 High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.EBI Membrane Research Group of the Hungarian Academy of Sciences
16460798 2 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.EBI Hospital for Sick Children
15007102 3 HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).EBI University of Washington
12533678 10 Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.EBI Japanese Foundation for Cancer Research
18678495 41 Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).EBI University of Bonn
22541068 73 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.EBI Uppsala University
23017888 26 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.EBI University of Bonn
22449016 6 Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.EBI BMSSI UMR 5086 CNRS /Universit£ Lyon 1
22366653 3 Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.EBI Gilead Sciences, Inc.
22165858 8 Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.EBI CNRS/Universit£ Lyon 1
20627559 6 Inhibition of ABCG2-mediated drug efflux by naphthopyrones from marine crinoids.EBI NCI-Frederick
19170519 34 Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.EBI University of Regensburg
18257545 34 Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.EBI Universita degli Studi di Bari
17317193 14 Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.EBI UMR 5063 CNRS/Universit£ Joseph Fourier-Grenoble I
17341062 2 Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors.EBI UMR 5086 CNRS/Universit£ Lyon 1
22112540 70 Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.EBI University of Bonn
21570282 28 Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).EBI Universidad Nacional de Colombia
21275386 13 Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.EBI Center for Cancer Research, NCI-Frederick
21189339 5 Interaction potential of etravirine with drug transporters assessed in vitro.EBI University Hospital Heidelberg
21354800 77 Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).EBI University of Bonn
20097565 12 Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter.EBI Ritsumeikan University
19932960 47 Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).EBI University of Bonn
19580319 40 Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships.EBI University of Bonn
19053888 114 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties.EBI Universita degli Studi di Bari
18089721 10 New inhibitors of ABCG2 identified by high-throughput screening.BDB SAIC-Frederick
19555120 11 Botryllamides: Natural Product Inhibitors of ABCG2.BDB SAIC-Frederick